Research progress of an immune checkpoint molecule VISTA in hematological tumors

VernacularTitle:免疫检查点分子VISTA在血液系统肿瘤中的研究进展
Author: Zi-Jun TANG ¹ ; Han-Xue ZHENG ; Hao XIONG ; Lian-Sheng ZHANG ; Li-Juan LI
Author Information

1. 兰州大学第二医院血液科,甘肃兰州 730030
Keywords: V-domain immunoglobulin suppressor of T-cell activation; immune checkpoint; hematological tumor; immunotherapy
From: Medical Journal of Chinese People's Liberation Army 2025;50(6):672-678
CountryChina
Language:Chinese
Abstract: Research on immune checkpoints such as programmed death protein-1(PD-1)and cytotoxic T lymphocyte antigen-4(CTLA-4)has provided new directions for tumor treatment.V-domain immunoglobulin suppressor of T-cell activation(VISTA)is an emerging immune checkpoint within the B7 family.Functioning as both a ligand and a receptor,VISTA is an inhibitory immune checkpoint molecule expressed in tumor cells,myeloid cells and T lymphocytes.It plays a crucial role in regulating autoimmunity,inflammatory response and tumor immunity.The non-redundant interactions between VISTA and other immune checkpoints,such as PD-1,may offer new therapeutic strategies and serve as a new target for overcoming immunotherapy resistance.This review summarizes the recent research progress on VISTA in hematological tumors,aiming to provide new insights into its application in the treatment of these malignancies.